| Literature DB >> 26557388 |
Sherif Hosny1, Francesco Strambi2, Nidhi Sofat3, Richard Field4.
Abstract
Synovial tissue can display an inflammatory response in the presence of OA. There is increasing interest to better understand the role of inflammation in OA, particularly with regard to those who require joint replacement. A systematic review of inflammatory synovitis in OA of literature databases was undertaken from their inception until October 14, 2014. Independent critical appraisal of each study was undertaken using the CASP appraisal tool. From a total of sixty-six identified citations, twenty-three studies were deemed eligible for review. The studies presented moderate to strong methodological quality. Strong correlation was identified between histological and imaging synovitis severity. Correlation was weaker between clinical symptoms and imaging and/or histological synovitis severity. There was little consensus, with regard to expressed cytokines and chemokines at the different stages of OA disease progression. Few studies investigated the influence of inflammatory synovitis on the outcome of major joint replacement. Research into inflammatory synovitis in OA is an emerging field. Longitudinal studies applying proven imaging modalities, histological analysis, and longer follow-up are required in order to further define our understanding of the role of synovitis in the pathogenesis of OA and its effects on outcomes following major joint replacement.Entities:
Year: 2015 PMID: 26557388 PMCID: PMC4628772 DOI: 10.1155/2015/729410
Source DB: PubMed Journal: Arthritis ISSN: 2090-1992
Summary of the critical appraisal score (full papers only).
| Study | CASP criterion number | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | Total | |
| Benito et al., 2005 [ | Y | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | 10 |
|
De Lange-Brokaar et al., 2014 [ | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | 11 |
| Lambert et al., 2014 [ | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | 11 |
| Liu et al., 2010 [ | Y | Y | Y | N | N | N | Y | N | Y | Y | N | 6 |
| Oehler et al., 2002 [ | Y | Y | N | Y | N | N | Y | Y | Y | Y | Y | 8 |
|
| ||||||||||||
| Østergaard et al., 1998 [ | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | 11 |
| Scanzello et al., 2009 [ | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | 11 |
| Smith et al., 1997 [ | Y | Y | N | Y | N | N | Y | Y | Y | Y | Y | 8 |
| Takase et al., 2012 [ | Y | Y | N | N | N | N | Y | Y | Y | Y | Y | 7 |
| Tanavalee et al., 2011 [ | Y | Y | Y | Y | N | N | Y | Y | Y | Y | N | 8 |
| Waldstein et al., 2014 [ | Y | Y | Y | Y | Y | N | Y | Y | Y | Y | N | 9 |
| Walther et al., 2001 [ | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | 11 |
| Walther et al., 2002 [ | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | 11 |
Y: yes; N: no.
(1) Did the study address a clearly focused issue?
(2) Was the cohort recruited in an acceptable way?
(3) Was the exposure accurately measured to minimize bias?
(4) Was the outcome accurately measured to minimize bias?
(5) Have the authors identified all important confounding factors?
(6) Have they taken account of the confounding factors in the design and/or analysis?
(7) Was the follow-up of subjects complete enough?
(8) Was the follow-up of subjects long enough?
(9) Do you believe the results?
(10) Can the results be applied to the local population?
(11) Do the results of this study fit with other available evidences?
Figure 1PRISMA flowchart.
Study design and characteristics.
| Study | OA/RA | Surgical intervention | Imaging modality | Synovial tissue scoring | Markers measured | Clinical scoring system | Result |
|---|---|---|---|---|---|---|---|
| Benito et al., 2005 [ | OA | TKR or arthroscopy | XR | N/A | Inflammatory cell infiltrate, blood vessel formation, angiogenic factors, NF-kB activation, TNF | NA | Early OA tissue exhibited greater lining layer thickness and greater CD4+ T cell and CD68+ macrophage infiltration; also more numerous blood vessels and VEGF and ICAM-I expression and greater numbers of cells producing TNF |
|
| |||||||
| De Lange-Brokaar et al., 2013 (abstract) [ | OA | Arthroscopy | Contrast enhanced MRI | Guermazi et al. MRI scoring system | N/A | VAS pain | Knee synovitis severity on MRI correlated with macroscopic and microscopic histological synovitis features but not with VAS pain |
|
| |||||||
| De Lange-Brokaar et al., 2013 (abstract) [ | OA | Arthroscopy or TKR | Contrast enhanced MRI | Guermazi et al. MRI scoring system | N/A | Different patterns of knee synovitis were correlated to knee pain scoring systems | |
|
| |||||||
| De Lange-Brokaar et al., 2014 [ | OA | Arthroscopy or TKR | Gd-DOTA MRI 3T | Krenn et al. system, lining cell layer, synovial stroma, and inflammatory infiltrate graded 0–3 | N/A | N/A | Synovitis severity on MRI correlated with macro- and microscopic features of synovitis in knee OA |
|
| |||||||
| Liang et al., 2009 (abstract) [ | OA | TKR or arthroscopy or Anterior Cruciate Ligament (ACL) reconstruction | N/A | Synovial CD31, NF-xB, MMP-1, COX-2, IL-1 | JKOM | Synovium MMP-1, COX-2, and IL-1 | |
|
| |||||||
| Lambert et al., 2014 [ | OA | TKR | N/A | Surgeon graded macroscopic criteria by Ayral et al. normal, reactive, and inflamed | Cytokines, chemokines, enzymes, anabolism, catabolism, and angiogenesis compounds | N/A | Inflammation, cartilage metabolism, Wnt signalling, and angiogenesis pathways were upregulated in areas of inflamed synovium |
|
| |||||||
| Liu et al., 2010 [ | OA | TKR | Gd-MRI 1.5T | Histological parameters 0–3 | N/A | JKOM, VAS, and WOMAC | Neither synovitis nor Gd-MRI score correlates with pain VAS score or WOMAC; they only correlated with JKOM score |
|
| |||||||
| Oehler et al., 2002 [ | OA | TKR or arthroscopy | N/A | Scored 0–4, immunohistochemistry | Inflammatory infiltrates | N/A | 4 subtypes of synoviopathy characterised; hyperplastic in early OA; inflammatory in early and late OA; fibrotic and detritus rich in late OA |
|
| |||||||
| Østergaard et al., 1998 [ | OA and RA | Knee arthroscopy or arthrotomy | Gd-DTPA MRI 1.5T | Histological parameters 0–3 | N/A | N/A | Dynamic MRI can be used to determine synovial inflammation but could not differentiate between moderate and severe inflammation |
|
| |||||||
| Scanzello et al., 2009 [ | OA | TKR | XR | N/A | IL-15, IL-6, IL-1 | N/A | Lymphocytic infiltrates found in all early OA specimens but only in some end stage specimens; IL-15 significantly higher in early OA patients |
|
| |||||||
| Smith et al., 1997 [ | OA | TKR or arthroscopy | N/A | Scored 0–4, immunohistochemistry | IL-1 | N/A | Synovial membrane inflammation more severe with advanced OA |
|
| |||||||
| Takase et al., 2012 [ | OA and RA | TKR | GSUS, PDUS, and Gd-DTPA 1.5T MRI | OMERACT-RAMRIS (0–3), histopathology 0–3 | Immunohistochemistry CD68, Ki-67, and CD31 | N/A | GSUS, PDUS, and MRI correlated with pathological total synovitis score; only PDUS and MRI showed high correlation with immunohistochemical parameters (CD68 for inflammatory cell infiltrate, Ki-67 for synovial lining cell thickness, and CD31 for vascularity) |
|
| |||||||
| Tanavalee et al., 2011 [ | OA | TKR | N/A | N/A | Serum CRP, ESR, and IL-6 | American Knee Society score and knee surface temperature | Synovectomy at the time of TKR does not benefit the outcome nor shorten the duration of the inflammatory response |
|
| |||||||
| Walther et al., 2001 [ | OA AND RA | TKR | Power Doppler sonography (PDS) | Vascularity graded 1–4 | N/A | N/A | PDS reliable in qualitative grading of synovial tissue vascularity in knees |
|
| |||||||
| Walther et al., 2002 [ | OA and RA | THR | PDS | Vascularity graded 1–4 | N/A | N/A | PDS reliable in qualitative grading of synovial tissue vascularity in hips |
|
| |||||||
| Waldstein et al., 2014 [ | OA | TKR | MRI 1.5 or 3T | WORMS scoring system; Krenn et al. synovium grading system, lining cell layer, synovial stroma, and inflammatory infiltrate graded 0–3 | Synovial WBC count, Mankin cartilage grading system; aggregate and dynamic modulus cartilage biomechanics | N/A | Cartilage mechanically inferior in knees with WBC >150 WBCs/mL compared to knees with <150 WBCs/mL; MRI and histopathologic synovitis grades did not correlate with each other or aggregate or dynamic cartilage modulus |
Genes differentially expressed between normal/reactive and inflamed areas of synovium.
| Compound | Upregulated | Downregulated |
|---|---|---|
| Inflammatory cytokines | IL8, IL6, TNFRSF21, IFI30, TNFAIP6, and IRF8 | |
|
| ||
| Inflammatory chemokines | CXCL5, CXCL6, CXCL16, CXCL2, and CXCL1 | |
|
| ||
| Inflammatory enzymes | ALOX5AP, PLD1, ALOX5, PTGES, PLCB1, SOD2, TBXAS1, PI3, and PLA2G4A | |
|
| ||
| Other inflammatory compounds | TREM1, S100A9, OSM, and PPARG | |
|
| ||
| Anabolism | HAS1, BMP6, and COLL22A1 | COL1A2, VIM, MATN2, HABP4, HAPLN1, HAS3, COL16A1, CILP, COL6A3, GPC4, HAPLN1, and ACAN |
|
| ||
| Catabolism | MMP9, MMP3, CTSH, ADAMDEC1, and CTSS | |
|
| ||
| Angiogenesis | STC1, PF4V1, EDNRB, AQP9, HBEGF, BDKRB1, RCAN1, ECGF1, DNER, BDKRB2, and PECAM1 | PDGFC and RNH1 |
IL: Interleukin, TNFRS: tumour necrosis factor receptor, and IFI30: gene for encoding Gamma-interferon-inducible lysosomal thiol reductase. TNFAIP6: tumor necrosis factor alpha-induced protein 6, IRF: interferon regulatory factor, CXCL: chemokine ligand, and ALOX5AP: 5-lipoxygenase activating protein encoded by the ALOX5AP gene. PLD: phospholipase D1 enzyme that is encoded by the PLD1 gene, PTGES: prostaglandin E synthase is an enzyme encoded by the PTGES gene, PLCB1: 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase beta-1 is an enzyme encoded by the PLCB1 gene, and SOD2: superoxide dismutase 2 enzyme encoded by the SOD2 gene. TBXAS1: thromboxane A synthase 1 enzyme encoded by the TBXAS1 gene, PI3: elafin, PLA2G4A: cytosolic phospholipase A2 enzyme encoded by the PLA2G4A gene, TREM1: triggering receptor expressed on myeloid cells 1 protein encoded by the TREM1 gene, S100A9: migration inhibitory factor-related protein 14, OSM: oncostatin M, PPARG: peroxisome proliferator-activated receptor gamma, HAS1: hyaluronan synthases 1, BMP: bone morphogenetic protein, COL: collagen, VIM: vimentin, MATN: cartilage matrix protein, HABP: hyaluronan-binding protein, HAPLN: proteoglycan link protein, HAS: hyaluronan synthase, CILP: intermediate layer protein, GPC: cerebroglycan, ACAN: aggrecan, MMP: metalloproteinase, CTSH: cathepsin H, ADAMDEC1: ADAM-like, decysin 1, CTSS: cathepsin S, STC1: stanniocalcin-1, EDNRB: endothelin receptor type B, AQP9: aquaporin-9, HBEGF: heparin-binding EGF-like growth factor, BDKRB1: bradykinin receptor B1, RCAN1: Down syndrome critical region gene 1, ECGF1: platelet-derived endothelial cell growth factor, DNER: Delta and Notch-like epidermal growth factor-related receptor, BDKRB2: bradykinin receptor B2, PECAM1: platelet endothelial cell adhesion molecule, PDGFC: platelet-derived growth factor C, and RNH1: ribonuclease inhibitor.